A Study of the Use of Dextroamphetamine in Aphasia 

 Home          About        Publications      Projects      People       Volunteer           Links 


Recent studies have suggested that the outcome of speech/language therapy, the primary form of treatment for aphasia, can be enhanced by adjuvant pharmacological treatment with low doses (20 mg) of dexamphetamine (D-AMPH) (Walker-Batson et al., 2001). The precise manner by which D-AMPH may improve outcome remains to be elucidated, but may relate to its noradrenergic and dopaminergic influences on attention and working memory. 

We are conducting a randomized double-blind, crossover study of patients with chronic aphasia that will utilize functional magnetic resonance imaging (fMRI) to examine the effects of D-AMPH on cerebral activation during performance of language tasks.

The specific aims are to: 1) ascertain whether low dose D-AMPH results in systematic changes in language-related neural activation as measured with fMRI in patients with aphasia compared to placebo. 2) determine whether low dose D-AMPH-induced alterations in activation vary with task demands; 3) delineate whether low dose D-AMPH augments attention, attention, working memory in aphasia; and 4) establish the correlation between patterns of cerebral activation and performance on behavioral measures of hemispheric asymmetries in language organization. 

If you know someone with aphasia who would be interested in participating they may contact:

Dr. Gerry A Stefanatos 
Cognitive Neurophysiology Lab
Temple University
215-204-8402 |

Dr. Ian Maitin
Chairperson, Physical Medicine and Rehabilitation
Temple University Hospital
215-707-7021 |

Andrew DeMarco, MA
Cognitive Neurophysiology Lab
Temple University
215-204-2826 |

 Walker-Batson, D., Curtis, S., Natarajan, R., Ford, J., Dronkers, N., Salmeron, E., et al. (2001). A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia. Stroke, 32(9), 2093-2098.